Mercury Pharmaceuticals

28

Sep 2026

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal. The study is by Dr Hunter Thomas Hoffman, Eli Lilly and Company, Indianapolis, IN, USA – the sponsor of the study and manufacturer of orforglipron – and colleagues.

READ MORE

28

Sep 2026

Study links insomnia to higher stroke and hospitalization risks

Insomnia is associated with a 26% higher risk of stroke and 28% higher odds of hospital admission, according to new research in Sleep Medicine Reviews. The researchers say the findings support recognizing insomnia as an important marker of brain, mental and general health.

READ MORE

28

Sep 2026

Research makes strong case for broader use of GLP1 drugs to protect hearts

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

READ MORE

28

Sep 2026

Continuous glucose monitors show strong survival benefits for type 2 diabetes patients

People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

READ MORE

28

Sep 2026

New EASD study highlights red meat sugar as independent risk factor for type 2 diabetes

Preliminary results of an observational study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2), reveal that a sugar called dietary N-glycolylneuraminic acid (Neu5Gc), which is common in red meat, is independently associated with a 63% higher risk of developing type 2 diabetes (T2D) in those with the highest versus lowest consumption, even after taking into account other T2D risk factors such as level of physical activity, overall diet, smoking status and other health conditions.

READ MORE

28

Sep 2026

New EASD study highlights red meat sugar as independent risk factor for type 2 diabetes

Preliminary results of an observational study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2), reveal that a sugar called dietary N-glycolylneuraminic acid (Neu5Gc), which is common in red meat, is independently associated with a 63% higher risk of developing type 2 diabetes (T2D) in those with the highest versus lowest consumption, even after taking into account other T2D risk factors such as level of physical activity, overall diet, smoking status and other health conditions.

READ MORE

28

Sep 2026

An AI-identified biomarker can look accurate and still fail its biggest test

The review examines how AI combines molecular, imaging, circulating, cellular, and digital data to identify potential disease biomarkers. Its authors argue that independent validation, biological testing, and evidence of better clinical decisions are needed before those candidates enter patient care.

READ MORE

28

Sep 2026

A survey of 371,000 adults links heart disease to eating whole fruit less often

In a survey analysis of 371,038 US adults, those reporting high blood pressure, high cholesterol, a heart attack, or coronary heart disease ate whole fruit slightly less often than those without the respective conditions. After adjustment, 100% fruit-juice consumption was less frequent among adults with high cholesterol and more frequent among those reporting a heart attack, but the cross-sectional study cannot establish cause and effect.

READ MORE

27

Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

READ MORE

27

Sep 2026

Low-dose radiation shows lasting benefits in patients with knee osteoarthritis

Low-dose radiation therapy may do more than relieve pain from early knee osteoarthritis, with a long-term analysis suggesting it could also influence how the disease progresses.

READ MORE